T0	Outcomes 35 70	renal blood flow and renal function
T1	Outcomes 184 228	effects on the treatment of severe hepatitis
T2	Outcomes 317 345	complication of renal damage
T3	Outcomes 349 370	hepatorenal syndrome.
T4	Outcomes 449 554	plasma renin activity (PRA), angiotensin II (AII), aldosterone (ALD), renal blood flow and renal function
T5	Outcomes 929 950	Basic autohemotherapy
T6	Outcomes 1230 1231	.
T7	Outcomes 1232 1292	PRA, AII, ALD, renal blood flow and damage to renal function
T8	Outcomes 1369 1370	.
T9	Outcomes 1371 1385	Survival rates
T10	Outcomes 1471 1474	PRA
T11	Outcomes 1493 1504	ng·ml⁻¹·h⁻¹
T12	Outcomes 1520 1526	17.35)
T13	Outcomes 1612 1628	before treatment
T14	Outcomes 1648 1659	ng·ml⁻¹·h⁻¹
T15	Outcomes 1665 1672	(155.18
T16	Outcomes 1788 1798	days after
T17	Outcomes 1818 1825	(2.02 ±
T18	Outcomes 1832 1843	ng·ml⁻¹·h⁻¹
T19	Outcomes 1894 1917	pg/ml, t = 4.97 - 15.61
T20	Outcomes 2139 2157	23.15) ml/min, t =
T21	Outcomes 2356 2365	group vs.
T22	Outcomes 2366 2368	16
T23	Outcomes 2500 2529	with chronic severe hepatitis
T24	Outcomes 2536 2591	decrease PRA, AII and ALD levels significantly increase
T25	Outcomes 2618 2633	renal damage to